WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, and ACIST Medical Systems, Inc., a Bracco Group company, pioneer and global market leader of advanced imaging modalities for cardiology, are providing Fairview Southdale Hospital, Edina, MN three leading edge technologies that improve workflow.
"I am excited to work with both companies to bring innovative solutions to the cath lab that enhance patient care," said Gregory Helmer, MD, FACC, Co-Director of Medical Research, Fairview Southdale Hospital. "Rapid FFR and Robotic PCI are significant contributions to PCI procedures and may improve safety, lesion assessment, and bring further precision to our interventional procedures."
The CorPath® System is the first FDA-cleared robotic-assisted system for percutaneous coronary intervention, offering robotic precision that may improve clinical outcomes and protection for physicians and staff from serious occupational hazards in the cath lab. The ACIST RXi technology provides the reassurance of accurate and reliable FFR measurements and the advantages of Rapid Exchange technology. ACIST CVi simplifies contrast injection for procedures while enhancing safety, efficiency, control and image quality.
"Both Corindus and ACIST share the strong vision of how physicians and their teams should operate in the cath lab,” said Mark Toland, Chief Executive Officer, Corindus Vascular Robotics. “This collaboration is the first step towards realizing this vision by providing innovative solutions to optimize workflow, improve safety, and eventually enhance patient care.”
“We look forward to furthering the reach of Corindus and ACIST so that more clinicians and patients can benefit from these advanced technologies,” said Tom Morizio, President & COO, ACIST Medical Systems, Inc. “The ultimate goal of this collaboration is to advance the science of interventional cardiology to provide the best care possible for patients.”
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to complex, radial, coronary and peripheral procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.
ACIST Medical Systems, Inc., A Bracco Group company, is a pioneering interventional and diagnostic technology company with a portfolio of advanced products, including the world’s first Rapid Exchange FFR and High Definition IVUS systems. It is also a global market leader in advanced contrast imaging systems for cardiovascular angiography and radiology imaging. Through these products, ACIST is demonstrating its commitment to bringing unique and innovative technologies that simplify cardiovascular procedures and empower clinicians to treat patients with superior care. As part of the Bracco Group, ACIST benefits from the resources of a multinational conglomerate with broad expertise in cath lab technology and a dedication to continuous advancement. Headquartered in Eden Prairie, Minnesota, ACIST has worldwide presence with over 300 direct employees and facilities in Silicon Valley, The Netherlands, Shanghai and Tokyo. To learn more about ACIST, visit www.acist.com.
About Bracco Group
Bracco has headquarters in Milan, Italy, and was founded in 1927. It is active in the healthcare sector through Bracco Imaging (diagnostic imaging), Pharma (prescription and over-the-counter drugs), ACIST Medical Systems and HLT (cardiology) and the Centro Diagnostico Italiano diagnostic clinic. With approximately 3,300 employees, it has annual total consolidated revenues of over $1.2 billion Euro. Bracco operates in more than 90 countries worldwide. To learn more about Bracco Group, visit www.bracco.com.
Forward Looking Statements
Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Examples of such statements include statements regarding:
- that Rapid FFR and Robotic PCI are significant contributions to PCI procedures and may improve safety, lesion assessment, and bring further precision to interventional procedures;
- that the CorPath® System offers robotic precision that may improve clinical outcomes and protection for physicians and staff from serious occupational hazards in the cath lab;
- that ACIST RXi technology provides the reassurance of accurate and reliable FFR measurements and the advantages of Rapid Exchange technology and that ACIST CVi simplifies contrast injection for procedures while enhancing safety, efficiency, control and image quality; and
- that the collaboration is the first step towards realizing the strong vision of how physicians and their teams should operate in the cath lab by providing innovative solutions to optimize workflow, improve safety and eventually enhance patient care.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at http://www.corindus.com.